AR

Ashok Ranjani

Director Director DIN 02673497
DIN 02673497 First appointment May 2009 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashok Ranjani

Data last updated:

Ashok Ranjani was a Director at Stanpro Pharmaceutical Limited (2009–2015) and Director at Captos Pharma Private Limited (from 2012). The companies operate in Pharma.

DIN 02673497
Primary Designation Director
Industry Pharma
First Appointment 23 May 2009
Oldest Company Age 14 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Stanpro Pharmaceutical Limited U24231TZ1989PLC003047
Director23 May 20091989Active
Captos Pharma Private Limited U24200TZ2012PTC018852
Director18 Oct 20122012Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Captos Pharma Private Limited
Stanpro Pharmaceutical Limited
Premium access

Shareholding and investment profile for Ashok Ranjani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashok Ranjani

Ashok Ranjani was first appointed on 23 May 2009 as Director at Stanpro Pharmaceutical Limited. The most recent appointment on record is 18 Oct 2012 at Captos Pharma Private Limited.

Ashok Ranjani held 2 earlier board appointments: Stanpro Pharmaceutical Limited (Director, 23 May 2009 to 19 Mar 2015); Captos Pharma Private Limited (Director, from 18 Oct 2012).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available